Australia markets close in 1 hour 35 minutes

4D pharma plc (LBPS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.17+0.24 (+3.46%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5169.96M
Enterprise value 3111.3M
Trailing P/E N/A
Forward P/E 1-15.59
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)246.32
Price/book (mrq)3.03
Enterprise value/revenue 3161.31
Enterprise value/EBITDA 7-3.26

Trading information

Stock price history

Beta (5Y monthly) 2.92
52-week change 3-52.37%
S&P500 52-week change 334.63%
52-week high 315.50
52-week low 36.93
50-day moving average 38.94
200-day moving average 310.62

Share statistics

Avg vol (3-month) 322.57k
Avg vol (10-day) 351.5k
Shares outstanding 522.54M
Implied shares outstanding 6N/A
Float 11.17M
% held by insiders 10.00%
% held by institutions 10.99%
Shares short (30 Aug 2021) 410.44k
Short ratio (30 Aug 2021) 40.45
Short % of float (30 Aug 2021) 4N/A
Short % of shares outstanding (30 Aug 2021) 40.05%
Shares short (prior month 29 July 2021) 415.11k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Dec 2020


Profit margin 0.00%
Operating margin (ttm)-5,175.22%

Management effectiveness

Return on assets (ttm)-49.64%
Return on equity (ttm)-86.93%

Income statement

Revenue (ttm)690k
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)16.90%
Gross profit (ttm)690k
EBITDA -34.14M
Net income avi to common (ttm)-30.5M
Diluted EPS (ttm)-2.14
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)11.99M
Total cash per share (mrq)0.73
Total debt (mrq)1.19M
Total debt/equity (mrq)3.06
Current ratio (mrq)2.45
Book value per share (mrq)2.37

Cash flow statement

Operating cash flow (ttm)-27.27M
Levered free cash flow (ttm)-17.74M